Premium
Sperm protein 17 is expressed in primary and metastatic breast cancer
Author(s) -
ChirivaInternati Maurizio,
Ferrari Raffaele,
Yu Yuefei,
D’Cunha Nicholas,
Grizzi Fabio,
Cobos Everardo,
Jenkins Marjorie R
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.1079.21
Subject(s) - immunohistochemistry , breast cancer , ovarian cancer , antigen , cancer , medicine , ca15 3 , oncology , ca 15 3 , cancer research , pathology , biology , immunology
Objective. Breast carcinoma (BC) is a major health concern for millions of women. The cancer testis antigen (CTA) Sperm protein 17 (Sp17), has been identified in multiple myeloma and ovarian cancer. This study evaluated Sp17 expression in both normal breast tissue and primary invasive ductal BC. Methods. We analyzed Sp17 expression in 7 normal breast tissues, 22 primary BCs by immunohistochemistry (IHC) and three human cell by Western Blotting (WB). Summary of Results. No immunoreactivity was recognized in normal breast tissues while BCs showed strong cytoplasmic immunoreactivity with 15/22 positive cases (70%) for Sp17 protein. Conclusions. The data demonstrate the expression of Sp17 in breast cancer. Further studies will elucidate the role of Sp17 in BC, and its potential use as a BC immunotherapeutic target antigen.